Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are used to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. In Fiji, the market for bronchodilator drugs has been growing steadily in recent years.
Customer preferences: Patients in Fiji prefer bronchodilator drugs that are affordable and effective. There is a high demand for generic drugs as they are more affordable than branded drugs. Patients also prefer drugs that provide quick relief from respiratory symptoms.
Trends in the market: The market for bronchodilator drugs in Fiji has been growing due to the increasing prevalence of respiratory diseases. The rise in air pollution levels, smoking, and changing lifestyles have contributed to the increasing incidence of respiratory diseases. As a result, there is a growing demand for bronchodilator drugs in Fiji.
Local special circumstances: Fiji is a small island nation in the South Pacific with a population of around 900,000. The healthcare system in Fiji is underdeveloped, and there is a shortage of healthcare professionals. This has led to a lack of awareness about respiratory diseases and their treatment. The government has taken steps to improve the healthcare system, but more needs to be done to increase awareness about respiratory diseases and their treatment.
Underlying macroeconomic factors: Fiji's economy is heavily dependent on tourism, which has been adversely affected by the COVID-19 pandemic. The pandemic has also led to a shortage of medical supplies, including bronchodilator drugs. The government has taken steps to address this issue, but the supply chain for medical supplies remains disrupted. The economic slowdown has also led to a decrease in disposable income, which has affected the demand for bronchodilator drugs. However, the government's efforts to improve the healthcare system and increase awareness about respiratory diseases are expected to drive the growth of the bronchodilator drugs market in Fiji in the long term.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
